|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We found that DACT1 expression was silenced in eight (88.9%) of nine breast cancer cell lines, and its protein levels were obviously reduced in breast tumors compared with paired surgical-margin tissues.
|
23497530 |
2013 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we present evidence that DACT1 is an important positive regulator in colon cancer through regulating the stability and sublocation of β-catenin.
|
22470507 |
2012 |
|
Carcinoma, Transitional Cell
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Relationships among MTHFR a1298c gene polymorphisms and methylation status of Dact1 gene in transitional cell carcinomas.
|
23244112 |
2012 |
|
Neural Tube Defects
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Our biochemical analyses revealed that among the five mutations, N356K and R45W show loss-of-function or reduced activities in inducing Dishevelled2 (DVL2) degradation and inhibiting jun-N-terminal kinase (JNK) phosphorylation, implicating mutated DACT1 as a risk factor for human NTDs.
|
22610794 |
2012 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
The data showed that BM-MSCs from Mutant demonstrated a state of disease memory, depicted by an upregulated expression of inflammatory markers (IL-6, TNFα); increased stem cell recruitment (Oct-4, Sox-2) and proliferation rates (CD90+/CD29+, PDA, 'S' phase of cell cycle by FACS and BrdU incorporation); accelerated preadipocyte induction (Dact-1, PPARγ2) with a quantitative increase in mature adipocyte formation (Leptin); ILCAs, which were non-responsive to high glucose did confer the Obese/T2D memory in Mutants.
|
23144726 |
2012 |
|
Stomach Neoplasms
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
Moreover, promoter methylation of DACT1 was detected in 29.3% (60/205) of primary gastric tumors.
|
23073659 |
2012 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we present evidence that DACT1 is an important positive regulator in colon cancer through regulating the stability and sublocation of β-catenin.
|
22470507 |
2012 |
|
Secondary Neoplasm
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
DACT1 methylation was significantly associated with tumor metastasis (P < 0.05), invasion (P < 0.05) and advanced tumor stage (P < 0.0005).
|
23073659 |
2012 |
|
Gastrointestinal Stromal Tumors
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The genomic segment most frequently altered in mutated samples was the 14q23.1 region, which contains potentially novel tumor suppressors, including DAAM1, RTN1 and DACT1. siRNA-mediated RTN1 downregulation showed evidence for the potential role in GIST pathogenesis.
|
20548289 |
2010 |
|
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
|
0.010 |
Biomarker
|
disease |
BEFREE |
The clinical significance of aberrant promoter methylation of the canonical Wnt pathway antagonist genes (sFRP1, sFRP2, sFRP4, sFRP5, Wif1, Dkk3, and Hdpr1) and also putative tumor-suppressor gene Wnt5a, belonging to the non-canonical Wnt signaling pathway, was investigated in a large series of 75 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia by methylation-specific polymerase chain reaction.
|
18549404 |
2008 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we identify DACT3, a member of the DACT (Dpr/Frodo) gene family, as a negative regulator of Wnt/beta-catenin signaling that is transcriptionally repressed in colorectal cancer.
|
18538736 |
2008 |
|
Acute lymphocytic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that expression of the Wnt inhibitors sFRP1, sFRP2, sFRP4, sFRP5, WIF1, Dkk3, and Hdpr1 was down-regulated due to abnormal promoter methylation in ALL cell lines and samples from patients with ALL.
|
17148581 |
2007 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that expression of the Wnt inhibitors sFRP1, sFRP2, sFRP4, sFRP5, WIF1, Dkk3, and Hdpr1 was down-regulated due to abnormal promoter methylation in ALL cell lines and samples from patients with ALL.
|
17148581 |
2007 |
|
Adult Acute Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that expression of the Wnt inhibitors sFRP1, sFRP2, sFRP4, sFRP5, WIF1, Dkk3, and Hdpr1 was down-regulated due to abnormal promoter methylation in ALL cell lines and samples from patients with ALL.
|
17148581 |
2007 |
|
Hepatocarcinogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
To explore whether HDPR1, the human homologue of Dpr, has an anti-oncogenic role in hepatocarcinogenesis, we studied the expression of this gene in HCCs.
|
15580286 |
2005 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The DACT1 gene was hyper-methylated in 32 of 38 cases of nasopharyngeal carcinoma with lymph node metastasis, and the DACT1 gene was hyper-methylated in 7 of 24 cases of nasopharyngeal carcinoma without lymph node metastasis.
|
31182157 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
High expression of DACT1 may inhibit the invasion and metastasis of nasopharyngeal carcinoma cells.
|
31182157 |
2019 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MiR-324-3p promotes tumor growth through targeting DACT1 and activation of Wnt/β-catenin pathway in hepatocellular carcinoma.
|
29029464 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
We have shown that DACT1 promotes cancer cell proliferation in vitro and tumor growth in vivo and enhances the migratory and invasive potential of colon cancer cells.
|
22470507 |
2012 |
|
Malignant Neoplasms
|
0.020 |
PosttranslationalModification
|
group |
BEFREE |
The methylation rate of the Dact1 gene in cancer tissues was significantly higher in patients with lymph node metastasis than in those without lymph node metastasis (46.3% vs. 17.2%, P = 0.018).
|
23244112 |
2012 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
Biomarker
|
disease |
BEFREE |
The methylation rate of the Dact1 gene in cancer tissues was significantly higher in patients with lymph node metastasis than in those without lymph node metastasis (46.3% vs. 17.2%, P = 0.018).
|
23244112 |
2012 |
|
Tumor Cell Invasion
|
0.020 |
PosttranslationalModification
|
phenotype |
BEFREE |
DACT1 methylation was significantly associated with tumor metastasis (P < 0.05), invasion (P < 0.05) and advanced tumor stage (P < 0.0005).
|
23073659 |
2012 |
|
Primary malignant neoplasm
|
0.020 |
PosttranslationalModification
|
group |
BEFREE |
The methylation rate of the Dact1 gene in cancer tissues was significantly higher in patients with lymph node metastasis than in those without lymph node metastasis (46.3% vs. 17.2%, P = 0.018).
|
23244112 |
2012 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
We have shown that DACT1 promotes cancer cell proliferation in vitro and tumor growth in vivo and enhances the migratory and invasive potential of colon cancer cells.
|
22470507 |
2012 |
|
Liver carcinoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Furthermore, a CpG island located at the promoter region and exon 1 of the HDPR1 gene was methylated in 22 (51%) of human HCCs.
|
15580286 |
2005 |